This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Quality IHC testing: pre-analytical phase

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 05:13

Dr Wilko Weichert explains how to ensure quality PD-L1 immunohistochemistry testing in the pre-analytical phase. Please see the Summary of Product Characteristics and Risk Minimisation Materials for KEYTRUDA® (pembrolizumab) before making any prescribing decisions and for further information around PD-L1 testing.

to keep updated with the latest educational materials in PD-L1 testing

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01388 | Date of Preparation: February 2021

Quality IHC testing: pre-analytical phase

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 05:13

Dr Wilko Weichert explains how to ensure quality PD-L1 immunohistochemistry testing in the pre-analytical phase. Please see the Summary of Product Characteristics and Risk Minimisation Materials for KEYTRUDA® (pembrolizumab) before making any prescribing decisions and for further information around PD-L1 testing.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01388 | Date of Preparation: February 2021